Bocharov SN*, Mankov AV, Bocharova YuS, Morikov DD, Sorokina LV and Golub IE

Department of Anesthesiology - Resuscitation, Irkutsk State Medical University of the Ministry of Health of the Russian Federation, Irkutsk, Russia

*Corresponding Author: Bocharov SN, Department of Anesthesiology - Resuscitation, Irkutsk State Medical University of the Ministry of Health of the Russian Federation, Irkutsk, Russia.

Received: January 24, 2022; Published: February 21, 2022

Abstract

Despite the historical antiquity of fat embolism syndrome, its treatment remains a subject of de-bate and one of the significant medical problems, since none of the theories has a key link in its development, by influencing which one can effectively prevent and treat ittreated. In this regard, the aim of the work was to develop the pathogenesis of fat embolism syndrome and determine an effective, pathogenetically based, method of its treatment.

Material and Methods: In the main 85 patients who were performed: determination of the presence of fatty globules at various stages of underwent total hip arthroplasty (TETS), the following treatment; dynamics of lipid metabolism markers; cholesterol level; dynamics of bio-chemical criteria that made it possible to formulate the pathogenesis of fat embolism and determine the key link in its development. In 194 patients, studies were performed to determine the most effective method of prevention and treatment with various drug substrates.

Outcomes: In 79% of cases, during the performance of TETS operations, patients develop fatty hyperglobulemia. Based on the results of the studies performed, a scheme of pathogenesis of the syndrome of fat embolism/hyperglobulemia was formulated, the key link of which is the insufficiency of a hepatocyte (liver failure), acting on which it is possible to successfully stop its development. Medicinal substrates of prevention and treatment were: the traditionally prescribed solution of Essentiale H (Lipostabil); 5% alcohol solution in 5% glucose solution and pathogenetically based hepato protector "Hepasol A".

Conclusion: According to the results of the studies performed, it was established that the key link in the formation of fatty globulemia is the functional insufficiency of the hepatocyte. The use of a 5% solution of ethyl alcohol diluted in a 5% glucose solution is al-most identical in clinical effectiveness to the amino acid hepato protector, but with strict adherence to the technology of its use (calculated dosage of 0.5 g/kg of body weight is administered during the day)! Traditionally prescribed and used solution "Essentiale H" has neither clinical nor laboratory significance.

Keywords: Pathogenesis; Fat Embolism; Lipid Metabolism; Total Endoprosthetics

References

1. Bocharov SN., et al. “Prevention and treatment of experimental fat globulinemia”. In: Proceedings of IX Russian National Congress “Man and his Health”. Saint Petersburg (2004): 18-19.
2. Bocharov SN., et al. “Method of prevention of fat embolism in perioperative period: Patent 2326676 of the Russian Federation”. 17 (2008): 1.
3. Bocharov SN., et al. “Experimental study of efficacy of the prophylaxis and treatment of fat embolism syndrome”. Abstract submission of 17^th annual congress of European Society of Intensive Care Medicine. Berlin (2004): 104.
4. Han YT., et al. “Clinical features and neuroimaging findings in patients with cerebral fat embolism”. Chinese Medical Journal (Engl.)7 (2016): 874-876.
5. Husebye EE., et al. “Bone marrow fat in the circulation: clinical entities and pathophysiological mechanisms”. Injury 4 (2006): 8-18.
6. Jenkins K., et al. “Fat embolism syndrome and alective knee arthroplasty”. Canadian Journal of Anaesthesia 49 (2002): 19-24.
7. Johnson MJ., et al. “Fat embolism syndrome”. Orthopedics1 (1996): 41-49.
8. Ivanitsky GR., et al. “Blood changer "Perftoran"”. West. RAN 67.11 998-1013.
9. Kao SJ., et al. “Clinical and pathological features of fat embolism with acute respiratory distress syndrome”. Clinical Science (Lond.) 113 (2007): 279-285.
10. Kosova E., et al. “Fat embolism syndrome”. Circulation 3 (2015): 317-320.
11. Kornilov NV., et al. “Diagnostics of fat globulinemia in traumas and surgery of bones: methodical guidelines”. Saint Petersburg (2000): 24.
12. Kornilov NV and Kustov VM. “Fat embolism”. Saint Petersburg: Morsar AV 2 (001): 287.
13. Lin KY., et al. “Favorable outcome of cerebral fat embolism syndrome with a Glasgow coma scale of 3: a case report and review of the literature”. Indian Journal of Surgery1 (2015): 46-48.
14. Mironov NP. “Modern approaches to the prevention and intensive care of fat embolism”. Klin West 1 (1997): 48-51.
15. Prakash S., et al. “Role of interleukin-6 as an early marker of fat embolism syndrome: a clinical study”. Clinical Orthopaedics and Related Research 471 (2013): 2340-2346.
16. Plakhotina EN and Bocharov S.N. “Fat embolism”. Novosibirsk: Nauka (2009): 150.
17. Rebrova OYu. “Statistical analysis of medical data. Use of the application program package STATISTICA”. Moscow: Media Sfera, (2003): 312.
18. Vorobyov SI., et al. “On the issue of perfluorocarbon emulsifier”. Perfluoroorganic compounds in biological medicine - Pushchino 8 (1997): 143-147.

Citation

Citation: Bocharov SN., et al. “Fatty Embolism (Pathogenesis, Treatment)".Acta Scientific Orthopaedics 5.3 (2022): 34-41.

Copyright

Copyright: © 2022 Bocharov SN., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.